



EHSF 2025 – Dynamics in HS –



VILNIUS | FEBRUARY 12–14, 2025

14th CONFERENCE OF THE EUROPEAN
HIDRADENITIS SUPPURATIVA FOUNDATION



ehsf2025.com

TABLE OF CONTENTS

01 | WELCOME MESSAGE

03

02 | GENERAL INFORMATION

04

03 | ABOUT EHSF

Congresses	06
Our history	06
Last HSF, Inc. Board with European Participation	06
Inauguration of EHSF e.V.	07
Founding Members	07

04 | COMMITTEES

Organizing Committee	10
Scientific Committee	11
Health Care Providers	12

05 | FEBRUARY 12, 2025 PROGRAM WED

Overview	14
Program	15

06 | FEBRUARY 13, 2025 PROGRAM THU

Overview	18
Program	19

07 | FEBRUARY 14, 2025 PROGRAM FRI

Overview	24
Program	25

08 | POSTERS

30

09 | INDUSTRY PROGRAM

Program	50
Sponsors	54
Exhibition	57

10 | IMPRINT

59



WELCOME TO EHSF 2025

It is an immense pleasure to welcome you to the 14th European Hidradenitis Suppurativa Foundation (EHSF 2025) Conference in Vilnius!

We discovered a pleasant coincidence: Vilnius is the number one dynamically developing city in CEE region. The expanding understanding of the enigmatic pathogenesis of Hidradenitis Suppurativa (HS) distinguishes it from other cutaneous inflammatory diseases and defines the dynamics for further research and treatment of this extraordinary skin condition. Despite existing enthusiasm, the development of innovative therapeutic armamentarium is undoubtedly needed. The motto "Dynamics in HS" has been chosen to reflect this need.

Due to its chronic, recurring and painful nature, HS isolates, stigmatizes patients and marks their life with deep psychological burden. On the other hand, it often becomes a challenge to involve the patient in the active control of his disease, to instill the desire to escape from the vicious circle of illness. Indeed, how many aspects remain to be clarified in order to improve the care of HS patients!

An exciting line-up of keynote speakers, panel discussions and research presentations promise to inspire and stimulate your intellectual curiosity. We hope that regardless of the winter season, the gathering of academic minds from around the world will create warm and unforgettable atmosphere that always accompanies EHSF conferences.

Representing vivid developments of science with one of the youngest communities in Europe, Vilnius is the home for numerous scientific institutions, the Vilnius University being the central one and also one of the oldest universities in Central and Eastern Europe.

On the Vilnius University observatory wall, there is the quote "Hinc itur ad astra", which means "from here the way leads to the stars". In today's distracted world, let this be the thought that brings us all together for innovation, friendship, respect and peace.



Dr. Rūta Gancevičienė
Conference President
President of the Lithuanian Association
of Dermatovenerology

GENERAL INFORMATION

LOCAL ORGANIZING COMMITTEE

Rūta Gancevičienė (conference president)

Skaidra Valiukeviciene

Vesta Kucinskiene

Jolanta Cesiene

Tadas Raudonis

Laura Lukaviciute

Tomas Vileikis

OVERALL LEARNING OBJECTIVES

- To provide outstanding scientific and educational content focused on hidradenitis suppurativa.
- To exchange ideas in the field of hidradenitis suppurativa and related topics, within an international scientific forum.
- To address the theoretical and practical aspects of hidradenitis suppurativa.

CME ACCREDITATION

An application has been made to the UEMS EACCME® for CME accreditation of this event.

CERTIFICATES

The certificate of attendance will be sent to you by e-mail/online download after the conference.

PRIZES & AWARDS

Best contribution prizes raised by EHSF e.V.

1st prize 1000 €

2nd prize 700 €

3rd prize 400 €

4th prize 200 €

5th prize 100 €

Young investigators prizes raised by EHSF e.V.

3 prizes of 200 € for active participants under 30 years old (lectures/poster presenters - who have to apply for the prize with CV, including date of birth and abstract submission).

Prize for best contribution from nurses

One prize of 200 € for active nurse participant (lectures/poster presenters).

EHSF e.V. Scholarships for participants from countries in Africa

The EHSF e.V. announces 3 scholarships for participants from African countries, who want to actively contribute to the 14th Conference, 12.-14.2.2025 in Vilnius. The scholarship requirement is an active participation to the Conference with a scientific contribution. Residents of Dermatology and Venereology will be prioritised. Each scholarship in the amount of 1000 € will be reimbursed after the Conference, following the presentation

of relevant invoices for travel expenses and accommodation.

REGISTRATION DESK OPENING HOURS

Wednesday, February 12, 2025

07:30–18:45

Thursday, February 13, 2025

07:30–18:30

Friday, February 14, 2025

07:30–14:00

WELCOME RECEPTION

Wednesday, February 12, 2025

18:30–20:00

Exhibition Hall

NETWORKING DINNER

(access only for participants with a reservation)

Palace of the Grand Dukes of Lithuania

Katedros a. 4,

01143 Vilnius

Thursday, February 13, 2025

Bus departure from Radisson BLU: 19:50

MEET THE EXPERTS

Friday, February 14, 2025

(access only for participants with a reservation)

14Horses

Dominikonų g. 11

01131 Vilnius

Start: 18:30

Individual arrival

LATEST PROGRAM

This book's content is as of 25.02.2025. For all updates please see the website.

► www.ehsf2025.com



ABOUT EHSF

CONGRESSES

The 1st International Hidradenitis Suppurativa (HS) Research Symposium took place on 30.3–2.4.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B.E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Ms. Michelle Barlow, USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA; Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Mr. Robert Howes, USA; Dr. Peter Hull, Canada; Dr. Gregor B.E. Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany. The 2nd International HS



Research Symposium took place on 5.3.2009 in San Francisco, CA, USA organized by Ms. Barlow and Profs. Paus and Zouboulis.

The 3rd and 4th International HS Research Symposia (first of the EHSF e.V.) took place on 27.–28.2.2014 and 19.–20.2.2015 in Brussels, Belgium.

The 5th International HS Conference, which was for the first time also open for non-members of the Society, took place on 10.–12.2.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6th International HS Conference took place on 8.–10.2.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7th International HS Conference took place on 10.–12.2.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8th International HS Conference took place on 10.–12.2.2019 in Wroclaw, Poland with 406 participants and 119 scientific contributions.

The 9th International HS Conference took place on 5.–7.2.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the

conference.

The 10th and 11th International HS Conferences took place – due to the COVID-19 pandemic – at a digital mode – on 10.–12.2.2021 with 688 participants from 52 countries and 138 scientific contributions, and on 9.–11.2.2022 with 598 participants from 48 countries and 138 scientific contributions, respectively. 12% of the active 11th conference participants were young scientists under the age of 30 years.

The 12th International HS Conference was organized on 8.–10.2.2023 in Florence as a hybrid event. 757 participants from 45 countries (599 onsite) with 198 scientific contributions undersigned the continuous growth of the EHSF e.V. events. Again, 10% of the active participants were young scientists under the age of 30 years.

The 13th International HS Conference took place 7.–9.2.2024 in Lyon as a presence only event. 695 participants from 51 countries with 193 scientific contributions, among them many young scientists, corroborated the importance of this annual scientific event.

OUR HISTORY

Founding of HSF, Inc.

In 2005, Ms. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the U.S. law. In addition to Ms. Barlow as president and co-

founder, Prof. Paus, director of basic research and co-founder, Prof. Zouboulis, director of clinical research and co-founder, Ms. Christine E. Pasela, San Diego, CA, USA, Ms. Sylvia Shawcross, Chelsea, Quebec, Canada, Ms. Mary Veta, San Diego, CA, USA, and Ms. Lynn Edward Wedell, San Diego, CA, USA constituted the HSF Board. Experimental Dermatology became the official scientific journal of the HSF, Inc.

LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.2.2012 a new HSF, Inc. board was elected with Prof. Zouboulis, President and responsible for hidradenitis suppurativa/acne inversa guidelines; Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research; Prof. Paus, vice president and responsible for experimental research, Ms. Barlow, treasurer and responsible for the Foundation; Prof. Richard Gallo, San Diego, CA, USA; Dr. Ichiro Kurokawa, Nishinomiya, Japan; Dr. George Varigos, Melbourne, Australia; Dr. Jan Lapins, Stockholm, Sweden; Dr. Paul Hazen, Westlake, OH, USA, responsible for patients' communication and for the HSF Inc. website, Thomas Winkler, Germany, president of the Deutsche Interessengemeinschaft Akne inversa e.V. as patients' representative; and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European

Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof. Zouboulis resigned as HSF, Inc. president and member of the board on 27.2.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 2.3.2013. During its first meeting on 24.3.2014 the new HSF, Inc. board has granted Ms. Barlow, Prof. Zouboulis and Prof. Paus the honorary Founders HSF, Inc. membership.

INAUGURATION OF EHSF E.V.

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.9.2012 in Prague, Czech Republic as independent, sister society of HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit organization (gemeinnütziger e.V.) according to the German law. General assemblies, take place annually during the

annual International Conference of the Society.

FOUNDING MEMBERS

- Dr. Jurr Boer,
Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol,
Brussels/Belgium
- Dr. Nemesha Desai,
London/United Kingdom
- Dr. Deirdre Nathalie Dufour,
Kalundborg/Denmark
- Dr. Lennart Emtestam,
Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec,
Roskilde/Denmark
- Dr. Łukasz Matusiak,
Wrocław/Poland
- Prof. Dr. Thrasivoulos Tzellos,
Harstad, Troms/Norway
- Thomas Winkler,
Lüdinghausen/Germany
- Dr. Hessel H. van der Zee,
Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis,
Dessau-Rosslau/Germany

OUTLOOK:

February 4–6, 2026

15th CONFERENCE OF THE EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION

Malta

Conference chair:

Michael Boffa

Vice-President of The Maltese Association of Dermatology and Venereology (MADV)

EHSF ORGANIZING COMMITTEE



RŪTA GANCEVIČIENĖ

(Vilnius, Lithuania)



PHILIPPE GUILLEM

(Ecully, France)



GREGOR B.E. JEMEC

(Roskilde, Denmark)



VÉRONIQUE DEL MARMOL

(Brussels, Belgium)



ERROL P. PRENS

(Rotterdam, The Netherlands)



FRANCESCA PRIGNANO

(Firenze, Italy)



THRASYVOULOS TZELLOS

(Bodø, Norway)



AXEL VILLANI

(Lyon, France)



CHRISTOS C. ZOUBOULIS

(Dessau, Germany)

SCIENTIFIC COMMITTEE

Benhadou, Farida

Cesiene, Jolanta

Christensen, Elisabeth M.M.

del Marmol, Veronique

Edek, Yusuf Can

Gančeviciene, Ruta

Garbayo Salmons, Patricia

Giamarellos-Bourboulis, Evangelos J.

Guillem, Philippe

Gulliver, Wayne

Haselgruber, Sofia

Herrera Calvo, Luis Felipe

Hórvath, Barbara

Ingram, John R.

Ioannidis, Dimitrios

Jemec, Gregor B.E.

Kristandt, Anna

Kucinskiene, Vesta

Li, Wei

Lukaviciute, Laura

Martorell, António

Marzano, Angelo V.

Matusiak, Łukasz

Molina-Leyva, Alesandro

Nikolakis, Georgios

Oon Hwee Boon, Hazel

Prens, Errol P.

Prignano, Francesca

Raudonis, Tadas

Romanelli, Marco

Rosi, Elia

Saunte, Ditte

Suppa, Mariano

Szepietowski, Jacek

Thomsen, Simon Francis

Tzellos, Thrasyvoulos

Valiukeviciene, Skaidra

Vilarrasa, Eva

Vileikis, Tomas P.

Villani, Axel

Vradeli, Georgia

Wainman, Hannah

Wortsman, Ximena

Zouboulis, Christos C.

HEALTH CARE PROVIDERS

OF THE EUROPEAN REFERENCE NETWORK OF RARE AND COMPLEX SKIN DISEASES (ERN SKIN)

The Department of Dermatology
Hôpital Erasme, Université Libre de
Brussels, Brussels, Belgium

The Department of Dermatology, Zealand
University Hospital, University of
Copenhagen, Roskilde, Denmark

The Departments of Dermatology,
Venereology, Allergology and Immunology,
Städtisches Klinikum Dessau,
Brandenburg, Medical School Theodor
Fontane and Faculty of Health Sciences
Brandenburg, Dessau, Germany



SCIENTIFIC PROGRAM

LATEST PROGRAM

For the latest program
version, please see the
website:

► www.ehsf2025.com



WEDNESDAY PROGRAM OVERVIEW

Wednesday, February 12, 2025 08:30–18:30			
	Room Alpha	Room Zeta 1	Room Beta
08:30	08:30–10:30 HS in the ERN Skin		
08:45			
09:00			
09:15			
09:30			
09:45			
10:00			
10:15	10:30–12:00 Working groups		10:15–12:30 Individual Poster Viewing
10:30			
10:45			
11:00			
11:15			
11:30			
11:45			
12:00	12:00–13:15 Lunch Break		12:30–13:15 Guided Poster Walk 01
12:15			
12:30			
12:45		12:30–14:45 Biologics' Session	
13:00			
13:15			
13:30	13:15–14:15 GHISA Part 1		
13:45			
14:00			
14:15	14:15–14:45 GHISA Part 2		
14:30			
14:45	14:45–15:45 Welcome, Opening & Invited Lectures		
15:00			
15:15			
15:30			
15:45		15:45–16:30 EHSF/Regeneron GWAS study	15:45–16:30 Guided Poster Walk 02
16:00	15:45–16:30 Coffee Break		
16:15	16:30–18:30 S-01 Basic HS		
16:30			
16:45			
17:00			
17:15			
17:30			
17:45			
18:00			
18:15			
18:30			
18:45	Get Together in the Exhibition Hall		
19:00			
19:15			

08:30–10:30	HS in the ERN Skin: Syndromic HS, HS-Related Autoinflammatory Syndromes Coordinators: <i>Veronique del Marmol, Angelo V. Marzano, Christos C. Zouboulis</i>	Room Alpha
10:30–12:00	Working Groups/Projects Basic HS research <i>Axel Villani, Evangelos J. Giamarellos-Bourboulis</i> Evidence-based decision making and outcomes <i>Thrasivoulos Tzellos, John R. Ingram</i> HS and antimicrobial stewardship <i>Francesca Prignano</i> Social dermatology in HS <i>Gregor B.E. Jemec, Elisabeth M. M. Christensen</i> Imaging in HS <i>Ximena Wortsman, Dimitros Ioannides</i> Surgical treatment <i>Philippe Guillem, Alejandro Molina-Leyva, Antonio Martorell</i> HS and wound healing <i>Marco Romanelli, Barbara Hörvath</i> New therapeutic assets <i>Georgios Nikolakis</i> HS and AI/social media <i>Tomas Vileikis, Sofia Haselgruber</i>	Room Alpha
10:15–12:30	Individual Poster Viewing	Room Beta
12:00–13:15	Lunch Break	Lobby
12:30–13:15	Guided Poster Walk 01 Group 1 Chair: <i>Axel Villani</i> Poster Topic: Basic HS Research (A-01-01 – A-01-15) Group 2 Chair: <i>Thrasivoulos Tzellos</i> Poster Topic: Evidence-based decisions making and outcomes (A-03-02 – A-03-14)	Room Beta
12:30–14:45	Biologics' Session Coordinator: <i>Georgios Nikolakis</i>	Room Zeta 1
13:15–14:15	GHISA: Global Hidradenitis Suppurativa Atlas - Part 1 Chair: <i>Gregor B.E. Jemec</i>	Room Alpha
13:15	Welcome, followed by a review of the organization and our achievements so far <i>Gregor B.E. Jemec, Denmark</i>	

13:30	Hidradenitis suppurativa morbidity in South Africa <i>Ameshin Moodley, South Africa</i>	
13:45	HS in Slovenia <i>Spela S. Baglama, Ljubljana, Slovenia</i>	
14:00	Discussion of the experience and plans for finishing GHISA1	
14:15–14:45	GHISA: Global Hidradenitis Suppurativa Atlas - Part 2 Chair: <i>Gregor B.E. Jemec</i> The purpose of GHISA2 <i>Gregor B.E. Jemec</i> Expanding the collaboration - new tasks and new opportunities Discussion	Room Alpha
14:45–15:45	Welcome Address and Opening Ceremony <i>Ruta Ganceviciene, Christos C. Zouboulis</i> <i>Prof. Dalius Jatuzis, Dean of the Faculty of Medicine, University of Vilnius</i> Invited Lecture Skin resident immune cells and their role in skin homeostasis and inflammation <i>Prof. Aurelija Žvirblienė, Institute of Biotechnology of Life Science Center, University of Vilnius, President of the Lithuanian Society of Immunology</i>	Room Alpha
15:45–16:30	EHSF/Regeneron GWAS study Coordinators: <i>Christos C. Zouboulis, Sofia Belouka</i> <i>Practical information on the initial steps and the logistics of the study program will be provided to the registered health care providers.</i>	Room Zeta 1
15:45–16:30	Guided Poster Walk 02 Group 1 Chair: <i>Veronique del Marmol</i> Poster Topic: Syndromic HS (A-02-01 – A-02-09) Group 2 Chair: <i>Marco Romanelli</i> Poster Topic: New therapeutic assets (A-10-27 – A-10-34) Group 3 Chair: <i>Francesca Prignano</i> Poster Topic: HS & antimicrobial stewardship (A-04-01), HS & Wound Healing (A-08-01 – A-08-02), HS & mental health (A-12-03 – A-12-04)	Room Beta
15:45–16:30	Coffee Break	Lobby
16:30–18:30	S-01 Basic HS Chairs: <i>Axel Villani, Tadas Raudonis, Evangelios J. Giamarellos-Bourboulis</i>	Room Alpha

16:30 S-01-01	Genetic characterization of a case-series of patients with acne fulminans and hidradenitis suppurativa: implication of genes involved in inborn errors of immunity <i>Aude Nassif</i>	
16:39 S-01-02	Genetic characterization of a case-series of patients with acne fulminans and hidradenitis suppurativa: implication of genes involved in inborn errors of immunity <i>Aude Nassif</i>	
16:48 S-01-03	Evidence of interferon-gamma pathway activation in hidradenitis suppurativa <i>Styliani Theochari</i>	
16:57 S-01-04	LAMA3 Mutation in Familial Hidradenitis Suppurativa Alters Keratinocyte Migration and Adhesion Dynamics <i>Paola Maura Tricarico</i>	
17:06 S-01-05	Study of microbiota and biomarkers in skin biopsies from patients with hidradenitis suppurativa <i>Mar Luque Luna</i>	
17:15 S-01-06	Investigating early events in hidradenitis suppurativa pathogenesis: Insights from hair follicle ex vivo models <i>Marta Bertolini</i>	
17:24 S-01-07	Exploratory study to analyze lesional versus perilesional inflammatory patterns of Hidradenitis suppurativa patients <i>Anke König</i>	
17:33 S-01-08	A genome-wide association meta-analysis on 4,814 patients and 1.2 million controls reveal that sequence variants that cause disruption of the Notch and Wnt/ β -catenin signaling is closely linked to the risk of developing hidradenitis suppurativa <i>Rune Kjærsgaard Andersen</i>	
17:42 S-01-09	Metabolic analysis in patients with moderate and severe hidradenitis suppurativa reveals changes in energy metabolism and utilization of circulating amino acids <i>Karolina Vorcakova</i>	
17:51 S-01-10	Deciphering the contribution of JAK-STAT pathways in hidradenitis suppurativa <i>Axel Villani</i>	
18:00 S-01-11	How do Hidradenitis suppurativa lesions evolve clinically? <i>Gregor B.E. Jemec</i>	
18:09 S-01-12	Variations in glucose metabolism-associated genes due to DNA methylation can increase the risk of metabolic abnormalities in hidradenitis suppurativa <i>Anveshi Koppula</i>	
18:18	General Discussion	
18:30	Get Together	Lobby

THURSDAY PROGRAM OVERVIEW

Thursday, February 13, 2025 08:00–18:30

	Room Alpha	Room Zeta 1	Room Beta
08:00			
08:15	08:00–09:00		
08:30	EHSF General Assembly		
08:45			
09:00	09:00–10:30		
09:15	S-02 Evidence-Based Decision Making and Outcomes (part 1)		
09:30			
09:45			
10:00			
10:15			
10:30			10:30–11:20
10:45	10:30–11:20 Coffee Break		Guided Poster Walk 03
11:00			
11:15			
11:30	11:20–12:30		
11:45	S-03 Social Dermatology and Mental Health in HS		
12:00			
12:15			
12:30	12:30–13:00 Lunch Break		
12:45			
13:00	13:00–14:00	13:00–14:00	
13:15	Lunch Industry Symposium	Patient Organizations' Representatives' Meeting	
13:30			
13:45			
14:00			
14:15	14:15–15:15		
14:30	Lunch Industry Symposium		
14:45		14:15–16:15	
15:00		Nurses' Session	
15:15	15:15–16:15		
15:30	S-04 Imaging HS		
15:45			
16:00			
16:15			16:15–17:00
16:30	16:15–17:00 Coffee Break		Guided Poster Walk 04
16:45			
17:00			
17:15	17:00–18:30		
17:30	S-05 New Therapeutic Assets 1		
17:45			
18:00			
18:15			
...			
19:15		19:15 Bus to location	
...			
20:00		20:00 Networking Dinner	

08:00–09:00	EHSF General Assembly	Room Alpha
09:00–10:30	S-02 Evidence-Based Decision Making and Outcomes (part 1) Chairs: <i>Thrasyvoulos Tzellos, Alejandro Molina-Leyva, Jolanta Cesiene</i>	Room Alpha
09:00 S-02-01	Prevalence and disease burden in patients with concomitant hidradenitis suppurativa and arthritis: a retrospective multicenter case-control study <i>Patricia Garbayo-Salmons on behalf of the Spanish Hidradenitis Suppurativa Group (GEHS).</i>	
09:09 S-02-02	European S2k guidelines for hidradenitis suppurativa / acne inversa <i>Christos C. Zouboulis</i>	
09:18 S-02-03	Assessment of patients' preference of patient reported outcome measures (PROMs) used in daily practice for hidradenitis suppurativa, a cross-sectional multi-center study <i>Johanna C. van Huijstee</i>	
09:27 S-02-04	Clinical and therapeutic implications of the anatomical distribution of hidradenitis suppurativa in 557 patients: upper, lower, atypical and progressor forms <i>Alejandro Molina-Leyva</i>	
09:36 S-02-06	Extraction of syndromic cases of HS from ERHS-Be registry database <i>Anne-Sophie Sarkis</i>	
09:45 S-02-07	Patients with type 1 diabetes are at increased risk of hidradenitis suppurativa – A population-based study <i>Ron Slama</i>	
09:54 S-02-08	Potential Clinical Factors Associated with Secukinumab Dose Selection in the Treatment of Hidradenitis Suppurativa: A Cohort Study of 132 Patients <i>Giovanna F. Osorio-Gomez</i>	
10:03 S-02-09	Antimicrobial Stewardship in Hidradenitis Suppurativa: A Multicentre Retrospective Study <i>Elia Rosi</i>	
10:12	General Discussion	
10:30–11:20	Coffee Break	Lobby
10:30–11:20	Guided Poster Walk 03 Group 1 Chair: <i>Gregor B.E. Jemec</i> Poster Topic: Social Dermatology in HS (A-05-01 – A-05-09) Group 2 Chair: <i>Ximena Wortsman</i> Poster Topic: Imaging in HS (A-06-02 – A-06-06)	Room Beta

Group 3 Chair: <i>Tadas Raudonis</i> Poster Topic: Basic HS research (A-01-37 – A-01-42)		
11:20–12:30	S-03 Social Dermatology and Mental Health in HS Chairs: <i>Gregor B. E. Jemec, Ruta Gancevičienė, Dimitrios Ioannidis</i>	Room Alpha
11:20 S-03-01	A Survey on Diet in Japanese patients with Hidradenitis Suppurativa compared with Healthy Individuals <i>Koremasa Hayama</i>	
11:29 S-03-02	The impact of hidradenitis suppurativa on sexual healths <i>Marie Gibaux</i>	
11:38 S-03-03	Patients' and dermatologists' experience and perspectives on current treatments for people living with hidradenitis suppurativa with draining tunnels <i>Antonio Martorell</i>	
11:47 S-03-04	French translation and validation of the HiSQOL quality of life questionnaire for hidradenitis suppurativa <i>Sébastien Berros</i>	
11:56 S-03-06	Introduction of the psychotherapy group and the hidradenitis suppurativa school in a tertiary care hospital (#103) <i>Juli Bassas</i>	
12:05 S-03-08	The psycho-emotional impact of Hidradenitis Suppurativa/Acne Inversa: patient's bodily experience, psychiatric comorbidity, self-esteem, coping styles and resilience. A cross-sectional study <i>Lucrezia Pacetti</i>	
12:14 S-03-09	Hidradenitis suppurativa impacts work life and daily activities more severely than psoriasis <i>Elena Sotiriou</i>	
12:23	General Discussion	
12:30–13:00	Lunch Break	Lobby
13:00–14:00	Lunch Industry Symposium For details see page 50	Room Alpha
13:00–14:00	Patient Organizations' Representatives' Meeting	Room Zeta 1
14:15–15:15	Lunch Industry Symposium For details see page 50	Room Alpha

14:15–16:15	Nurses' Session Technical chair: <i>Kristina Briede and Gintarė Budrytė (LIT)</i> Interactive Chair: <i>Jette Marcussen (DK)</i> Narrative Chair: <i>Stine Halgren Pedersen (DK)</i>	Room Zeta 1
14:15	Introduction to Hidradenitis suppurativa (HS) <i>Stine Halgren Pedersen (DK)</i>	
14:25	Patients with HS and their families' experiences of loss and need of well-being interventions: <i>Jette Marcussen (DK)</i>	
14:45	Emotional impact of HS: <i>Kritina Briede, Gintarė Budrytė</i>	
15:05	What's most important for the patient: <i>Barry McGrath (IR)</i>	
15:20	Pain management; non-pharmacological management / adjuvant treatment: <i>Christina Wilken (DK)</i>	
15:30	Nursing research: 2 poster presentation: Patients with HS and their family's needs of holistic nurse interventions: <i>Stine Halgren Pedersen (DK)</i>	
15:40	What did the session teach us about HS nursing?	
15:50	Evaluation/ Networking list	
15:15–16:15	S-04 Imaging in HS Chairs: <i>Ximena Wortsman, Thomas Vileikis, Veronique del Marmol</i>	Room Alpha
15:15 S-04-01	Tetra Continental Guidelines on the Use of Ultrasound in Hidradenitis Suppurativa: An Expert Delphi Consensus <i>Ximena Wortsman</i>	
15:24 S-04-02	Correlation of quantitative shear wave elastography and the histopathological findings in tunnels of hidradenitis suppurativa: a pilot cross-sectional study <i>Eva Vilarrasa</i>	
15:33 S-04-03	Pilot Project on AI-Assisted Ultrasound for Hidradenitis Suppurativa <i>Clara Ureña-Paniego</i>	
15:42 S-04-04	Role of Ultra-High-Frequency Ultrasound in the Detection and Surgical Management of Microtunnels in Hidradenitis Suppurativa: A Case Series <i>Giammarco Granieri</i>	

15:51	General Discussion	
16:15–17:00	Guided Poster Walk 04	Room Beta
	Group 1 Chair: <i>Evangelos J. Giamarellos-Bourboulis</i> Poster Topic: Basic HS research (A-01-16 – A-01-25)	
	Group 2 Chair: <i>John R. Ingram</i> Poster Topic: Evidence-based decision and outcomes (A-03-16 – A-03-25)	
	Group 3 Chair: <i>Łukasz Matusiak</i> Poster Topic: New therapeutic assets (A-10-01 – A-10-14)	
16:15–17:00	Coffee Break	Lobby
17:00–18:30	S-05 New Therapeutic Assets (part 1)	Room Alpha
	Chairs: <i>Łukasz Matusiak, Skaidra Valiukevičienė, Aude Nassif</i>	
17:00 S-05-01	The efficacy of continuous secukinumab treatment over two years, as measured by the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials <i>Christos C. Zouboulis</i>	
17:09 S-05-02	Early clinical development of CIT-013, a first in class NETosis inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers demonstrating potent inhibition of LPS induced Neutrophil Extracellular Trap formation <i>Leonie M. Middelink</i>	
17:18 S-05-03	Depth and Durability of the IHS4 Efficacy Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS) <i>Thrasyvoulos Tzellos</i>	
17:27 S-05-04	Depth of the Efficacy Response to Lutikizumab Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS) <i>Hermenio Lima</i>	
17:36 S-05-05	A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab in Adult Patients with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy <i>Falk G. Bechara</i>	

17:45 S-05-06	Metformin in conjunction with doxycycline is not superior to doxycycline monotherapy for Hidradenitis Suppurativa; results of a double-blinded, randomized placebo-controlled trial <i>Nicole D.K. Koerts</i>
17:54 S-05-07	Long-term efficacy of LAight therapy in patients with hidradenitis suppurativa <i>Alexandra Strobel</i>
18:03 S-05-08	SECU-SPAIN: Real-World Efficacy and Safety of Secukinumab in Hidradenitis Suppurativa - A 1-Year Follow-Up Analysis <i>Antonio Martorell</i>
18:12	General Discussion



FRIDAY PROGRAM OVERVIEW

Friday, February 14, 2025 08:00–17:15

	Room Alpha	Room Beta
08:00	08:00–09:20 S-06 New Therapeutic Assets (part 2)	
08:15		
08:30		
08:45		
09:00		
09:15	09:20–10:00 Coffee Break	09:20–10:00 Guided Poster Walk 05
09:30		
09:45		
10:00	10:00–11:45 S-07 Evidence-Based Decision Making and Outcomes 2	
10:15		
10:30		
10:45		
11:00		
11:15	12:00–12:45 Lunch Break	11:45–12:45 Guided Poster Walk 06
11:30		
11:45		
12:00		
12:15		
12:30	12:45–13:45 Lunch Industry Symposium	
12:45		
13:00		
13:15	13:45–15:10 S-08 Classical HS Treatment	
13:30		
13:45		
14:00		
14:15		
14:30	15:10–16:45 S-09 Surgical Treatment & Wound Healing	
14:45		
15:00		
15:15		
15:30		
15:45	16:45–17:15 Awards and Closure Address	
16:00		
16:15		
16:30	18:30–21:00 Experts' Dinner	
16:45		
17:00		
...		
18:15		
18:30		
18:45		
19:00		
...		
23:00		

08:00–09:20	S-06 New Therapeutic Assets (part 2) Chairs: <i>Vesta Kučinskienė, Barbara Hórvath</i>	Room Alpha
08:00 S-06-01	Effectiveness of secukinumab in patients with moderate to severe hidradenitis suppurativa: data from a real-world, managed access program <i>Maria M. Constantin</i>	
08:09 S-06-02	Bimekizumab impact on HS disease severity measured by IHS4 and draining tunnel count over 2 years: Data from BE HEARD EXT <i>Christos C. Zouboulis</i>	
08:18 S-06-03	Resolution of deep dermal inflammatory lesions (DDILs) with the Nanobody® sonelokimab: Abscess and draining tunnel outcomes from the Phase 2 MIRA trial <i>Jacek C. Szepietowski</i>	
08:27 S-06-04	IHS4 100 and other IHS4 outcomes with the Nanobody® sonelokimab: Week 24 results from the Phase 2 MIRA trial in patients with moderate-to-severe HS <i>John R. Ingram</i>	
08:36 S-06-05	Evidence of a role for IL-17F in the inflammatory mechanisms underlying hidradenitis suppurativa (HS), including in deep dermal tunnels <i>Kristian Reich</i>	
08:45 S-06-06	Patient Perspectives on topicals in Hidradenitis Suppurativa: Insights from a Danish Online Survey Cohort <i>Gregor B.E. Jemec</i>	
08:54	General Discussion	
09:20–10:00	Coffee Break	Lobby
09:20–10:00	Guided Poster Walk 05 Group 1 Chair: <i>Anna Kristandt</i> Poster Topic: Basic HS research (A-01-26 – A-01-36) Group 2 Chair: <i>Farida Benhadou</i> Poster Topic: Evidence-based decision making and outcomes (A-03-26 – A-03-32)	Room Beta
10:00–11:45	S-07 Evidence-Based Decision Making and Outcomes (part 2) Chairs: <i>John R. Ingram, Brian Kirby, Michael Boffa</i>	Room Alpha
10:00 S-07-01	The Right Treatment for the Right Patient: Therapeutic Drug Monitoring <i>Afsaneh Alavi</i>	

10:09 S-07-02	Bimekizumab impact on dichotomous IHS4 response levels over 2 years: Results from BE HEARD EXT <i>Thrasylvoulos Tzellos</i>	
10:18 S-07-03	Analysis of mortality in patients with chronic immunologic skin diseases from the Spanish big data-based DERMACLEAR study: focus on hidradenitis suppurativa <i>Raquel Rivera</i>	
10:27 S-07-04	Bimekizumab 2-year maintenance of response in Week 48 responders in moderate to severe HS: Data from BE HEARD EXT <i>Martina L. Porter</i>	
10:36 S-07-05	Sepsis or systemic inflammatory response syndrome in Hidradenitis Suppurativa? A clinical analysis. <i>Luciana V. Gomide</i>	
10:45 S-07-06	Cardiovascular profile of naive patients affected by hidradenitis suppurativa or psoriasis candidate to biologic therapy <i>Flavia Manzo Margiotta</i>	
10:54 S-07-07	Clinical and serological differences between familial and sporadic cases of hidradenitis suppurativa <i>Valentina Dini</i>	
11:03 S-07-08	Patient and physician evaluation of disease severity and lesion count in the SUNSHINE and SUNRISE Phase 3 trials for hidradenitis suppurativa: A post hoc analysis <i>John R. Ingram</i>	
11:12 S-07-09	North American guidelines for the management of hidradenitis suppurativa in special patient populations <i>Raed Alhusayen</i>	
11:21 S-07-10	Deep dermal inflammatory lesions (DDLs) drive symptom and quality-of-life burden for patients with moderate-to-severe HS: Insights from the MIRA trial population <i>Falk G. Bechara</i>	
11:30	General Discussion	
11:45-12:45	Guided Poster Walk 06 Group 1 Chair: <i>Philippe Guillem</i> Poster Topic: Surgical treatment (A-07-03 – A-07-16) Group 2 Chair: <i>Eva Vilarrasa</i> Poster Topic: Classical HS treatment (A-09-02 – A-09-09) Group 3 Chair: <i>Vesta Kucinskiene</i> Poster Topic: New therapeutic assets (A-10-16 – A-10-26)	Room Beta

12:00-12:45	Lunch Break	Lobby
12:45-13:45	Lunch Industry Symposium For details see page 51	Room Alpha
13:45-15:10	S-08 Classical HS Treatment Chairs: <i>Laura Lukavičiūtė, Angelo V. Marzano</i>	Room Alpha
13:45 S-08-01	Paradoxical psoriasiform reaction to adalimumab in hidradenitis suppurativa <i>Jose C. Pascual</i>	
13:54 S-08-02	Patient journey, referral patterns and healthcare resource utilization among patients with hidradenitis suppurativa: a nationwide register study <i>Simon F. Thomsen</i>	
14:03 S-08-03	A Machine Learning Approach to Identify Baseline Predictors of HiSCR From a Phase 2 Study With Povorcitinib <i>Leandro Santos</i>	
14:12 S-08-04	Retrospective evaluation of HS progression using Hurley grade and the scores IHS4 and HS-PGA <i>Anne-Sophie Sarkis</i>	
14:21 S-08-06	Acitretin in Patients with Follicular Variant of Hidradenitis Suppurativa According to Martorell's Classification: A Retrospective Analysis of a Series of 138 Case <i>Antonio Martorell-Calatayud</i>	
14:30 S-08-07	Adalimumab in the management of hidradenitis suppurativa: experience of a tertiary center <i>Patricia M. Gomes</i>	
14:39 S-08-08	Secukinumab in severe hidradenitis suppurativa (HS): a 2-week interval (Q2) confirms its superiority over 4-week (Q4) in a prospective real life study <i>Pierre-Andre Becherel</i>	
14:48	General Discussion	
15:10-16:45	S-09 Surgical Treatment & Wound Healing Chairs: <i>Philippe Guillem, Falk Bechara</i>	Room Alpha
15:10 S-09-01	Cost-utility analysis of clinic-based derofing versus local excision for hidradenitis suppurativa <i>Sabrina Hundal</i>	

- 15:19 S-09-02 Combined therapy of hidradenitis suppurativa in northern Greece: Do biologic agents and surgical management serve the gold standard?
Sofia-Andriani Theodorelou-Charitou
- 15:28 S-09-03 Preoperative ultrasound and long-term inflammatory control reduce the risk of recurrence in surgery for hidradenitis suppurativa: an analysis of 206 surgical interventions
Carmen García-Moronta
- 15:37 S-09-04 Combining deroofting with excision: A holistic approach to hidradenitis surgery
Michael Schenker
- 15:46 S-09-05 Hybrid wound closure - A new approach to hidradenitis suppurativa surgery
Yusuf C. Edek
- 15:55 S-09-06 Epigenetic Dysregulation Behind Impaired Wound Healing in Hidradenitis Suppurativa
Uppala Radhakrishna
- 16:04 S-09-07 Modified Incision & Drainage Procedure (M-IGD): Analysis of Recurrence Rate Compared with the Traditional Method - A Retrospective Analysis of 221 Cases
Antonio Martorell
- 16:13 S-09-08 Plasma Rich in Growth Factors (PRGF) for the Management of Second Intention Closure Healing in Hidradenitis Suppurativa: A Prospective Study in Clinical Practice
Alexandra Alturo-Pons
- 16:22 S-09-09 Combination of Anti-IL-17 Biologics and Radical Surgery for the Treatment of Patients with HS
Monika Arenbergerova
- 16:31 General Discussion

16:45-17:15 **Awards and Closure Address** Room Alpha

18:30-21:00 **Experts' Dinner**

[illegible][illegible]

POSTERS



A-01 Basic HS Research

Orals

- S-01-01** Genetic characterization of a case-series of patients with acne fulminans and hidradenitis suppurativa: implication of genes involved in inborn errors of immunity
Aude Nassif
- S-01-02** Antimicrobial Stewardship in Hidradenitis Suppurativa: A Multicentre Retrospective Study
Aude Nassif
- S-01-03** Evidence of interferon-gamma pathway activation in hidradenitis suppurativa
Styliani Theochari
- Poster Walk 01 – Group 1**
- A-01-01** Prevalence of comorbidities and smoking habits in hidradenitis suppurativa patients: a retrospective study
Ugnė Janonytė
- A-01-02** A scoping review of the impact of the menstrual cycle on exacerbations of hidradenitis suppurativa
Hannah Wainman
- A-01-03** Eosinophils in hidradenitis suppurativa: a clinicopathological study
Jose Pascual
- A-01-04** Dynamic Immune-mesenchymal interplay within the tertiary lymphoid structures promotes autoimmune pathogenesis in Hidradenitis Suppurativa
Catherine Lu
- A-01-05** Exploratory study to assess the nutritional status of patients with hidradenitis suppurativa using an online questionnaire
Isabel Rzehak

- A-01-06** Exploring Natural COX-2 Inhibitors for Pain Relief in Hidradenitis Suppurativa
Sergio Crovella
- A-01-08** Patients with hidradenitis suppurativa over 50 years old differ significantly from younger patients. An observational study from a Belgian cohort.
Lila Desmarest
- A-01-09** Vitamin D Status and Its Association with Hidradenitis Suppurativa Severity
Dimitra Koumaki
- A-01-10** Patients with Hidradenitis suppurativa and their families' needs of holistic nursing interventions.
Stine Pedersen
- A-01-11** Loss-of-function mutation in ABCD1 is a genetic predisposing factor of cigarette smoking patients with follicular hidradenitis suppurativa
Jiaqi Li
- A-01-12** Routine care of hidradenitis suppurativa in Germany - a snapshot
Frenz Ohm
- A-01-15** Modulation of vasoactive and endothelial mediators in hidradenitis suppurativa
Styliani Theochari
- Poster Walk 04 – Group 1**
- A-01-16** GJB3 mutation in familial Hidradenitis Suppurativa alter key processes in keratinocyte proliferation and differentiation
Elena Maria Nardacchione
- A-01-17** Viscoelastic Coagulation Monitoring in Hidradenitis Suppurativa: an observational study measuring blood coagulation in real time
Angeliki Vlysidou
- A-01-18** The Role of Keratinocyte Cell Junction Genes and Epidermal Barrier Dysfunction in Familial Hidradenitis Suppurativa
Paola Maura Tricarico
- A-01-19** LAMA3 Mutation in Familial Hidradenitis Suppurativa Alters Keratinocyte Migration and Adhesion Dynamics
Elena Maria Nardacchione
- A-01-20** Characterization of Hidradenitis Suppurativa Patients with Coexisting Inflammatory Bowel Diseases: A Retrospective Study Using the Belgian Hidradenitis Suppurativa Registry.
Maria Chaoui
- A-01-21** Pediatric hidradenitis suppurativa: Retrospective evaluation of clinical features, disease course and treatment methods in a tertiary care hospital
Yusuf Edek

- A-01-22** Blood systemic inflammation biomarkers in Hidradenitis Suppurativa: differences across phenotypes
Alessandra Michelucci
- A-01-23** Study of microbiota and biomarkers in skin biopsies from patients with hidradenitis suppurativa
Mar Luque Luna
- A-01-24** Histopathological features in active versus scarred Hidradenitis Suppurativa.
Elizabeth Keeling
- A-01-25** Concomitant Preauricular and Postauricular Hidradenitis Suppurativa: An Uncommon Clinical Manifestation
Hilmi Kilgin
- Poster Walk 05 – Group 1**
- A-01-26** Association of hidradenitis suppurativa and familial mediterranean fever: A case series
Emre Güven
- A-01-27** Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as Inflammatory Markers in Patients with Hidradenitis Suppurativa Undergoing Biologic Therapy
Elia Rosi
- A-01-28** Exploratory study to evaluate changes in inflammatory pattern in patients with active, moderate-to-severe hidradenitis suppurativa after a six-week treatment with adalimumab.
Tanja Ickelsheimer
- A-01-29** Investigating early events in hidradenitis suppurativa pathogenesis: Insights from hair follicle ex vivo models
Marta Bertolini
- A-01-30** Exploring the potential of selective BET inhibition as a treatment for Hidradenitis Suppurativa
Marta Bertolini
- A-01-31** Exploratory study to analyze lesional versus perilesional inflammatory patterns of Hidradenitis suppurativa patients
Anke König
- A-01-32** The first German contribution to the Global Hidradenitis suppurativa Atlas (GHISA): A prospective, cross-sectional study at the Klinikum Darmstadt, Germany
Marten Steinmetz
- A-01-33** A genome-wide association meta-analysis on 4,814 patients and 1.2 million controls reveal that sequence variants that cause disruption of the Notch and Wnt/ β -catenin signaling is closely linked to the risk of developing hidradenitis suppurativa
Rune Kjærsgaard Andersen

- A-01-34** Exploring the Potential Association Between Hidradenitis Suppurativa and Dental Anomalies in Bangladesh: A Clinical Perspective
Chowdhury Barua
- A-01-35** Metabolic analysis in patients with moderate and severe hidradenitis suppurativa reveals changes in energy metabolism and utilization of circulating amino acids
Karolina Vorcakova
- A-01-36** Deciphering the contribution of JAK-STAT pathways in hidradenitis suppurativa
Axel Villani
- Poster Walk 03 – Group 3**
- A-01-37** How do Hidradenitis suppurativa lesions evolve clinically?
Gregor B.E. Jemec
- A-01-38** A case of hidradenitis suppurativa with penil ulcer
Erkan Alpsoy
- A-01-39** Variations in glucose metabolism-associated genes due to DNA methylation can increase the risk of metabolic abnormalities in hidradenitis suppurativa.
Anveshi Koppula
- A-01-40** Worsening of hidradenitis suppurativa during chemotherapy treatments
Daniel González - Vilas
- A-01-41** Semaglutide as an adjunctive treatment for hidradenitis suppurativa: improves systemic inflammatory burden.
Lisa Killion
- A-01-42** IL-1 Gene Expression is Associated with Tendrils in Hidradenitis Suppurativa Lesional Skin
Kathleen Smith

A-02 Syndromic HS**Orals**

- S-02-01** Prevalence and disease burden in patients with concomitant hidradenitis suppurativa and arthritis: a retrospective multicenter case-control study
Patricia Garbayo-Salmons
- T-02-06** Extraction of syndromic cases of HS from ERHS-Be registry database
Anne-Sophie Sarkis
- Poster Walk 02 – Group 1**
- A-02-01** Challenges in Managing Severe Hidradenitis Suppurativa: A Case of Atypical Presentation and Multidisciplinary Approach
Amelia Gelson-Thomas
- A-02-04** Hidradenitis suppurativa and comorbidities in pediatric population: work-up.
Teresa Oranges

- A-02-05** Syndromic hidradenitis suppurativa- clinical profile and longtime follow up of 10 cases from Brazil
Maria Cecilia Rivitti-Machado
- A-02-06** Alopecia in Hidradenitis Suppurativa: study of 23 patients
Pablo Fernandez-Crehuet
- A-02-07** Immune-Mediated Inflammatory Diseases Associated with Hidradenitis Suppurativa
Rosa Fornons-Servent
- A-02-08** A rare case of peripheral ulcerative keratitis in hidradenitis suppurativa
Lisa Killion
- A-02-09** A case of thrombophlebitis migrans in a 38-year-old female with severe refractory hidradenitis suppurativa
Aikaterini Liakou

A-03 Evidence-based decision making and outcomes

Orals

- S-02-02** European S2k guidelines for hidradenitis suppurativa / acne inversa
Christos Zouboulis
- S-02-03** Assessment of patients' preference of patient reported outcome measures (PROMs) used in daily practice for hidradenitis suppurativa, a cross-sectional multi-center study
Alejandro Molina-Leyva
- S-02-04** Clinical and therapeutic implications of the anatomical distribution of hidradenitis suppurativa in 557 patients: upper, lower, atypical and progressor forms
Nana Aviaaja Rosena
- S-02-07** Patients with type 1 diabetes are at increased risk of hidradenitis suppurativa – A population-based study
Ron Slama
- S-02-08** Potential Clinical Factors Associated with Secukinumab Dose Selection in the Treatment of Hidradenitis Suppurativa: A Cohort Study of 132 Patients
Giovanna Osorio-Gomez
- S-07-01** The Right Treatment for the Right Patient: Therapeutic Drug Monitoring
Afsaneh Alavi
- S-07-02** Bimekizumab impact on dichotomous IHS4 response levels over 2 years: Results from BE HEARD EXT
Thrasyvoulos Tzello
- S-07-04** Bimekizumab 2-year maintenance of response in Week 48 responders in moderate to severe HS: Data from BE HEARD EXT
John Ingram

- S-07-06** Cardiovascular profile of naive patients affected by hidradenitis suppurativa or psoriasis candidate to biologic therapy
Flavia Manzo Margiotta
- S-07-07** Clinical and serological differences between familial and sporadic cases of hidradenitis suppurativa
Valentina Dini
- S-07-08** Patient and physician evaluation of disease severity and lesion count in the SUNSHINE and SUNRISE Phase 3 trials for hidradenitis suppurativa: A post hoc analysis
John Ingram
- S-07-09** North American guidelines for the management of hidradenitis suppurativa in special patient populations
Raed Alhusayen
- S-07-10** Deep dermal inflammatory lesions (DDILs) drive symptom and quality-of-life burden for patients with moderate-to-severe HS: Insights from the MIRA trial population
Falk Bechara

Poster Walk 01 – Group 2

- A-03-02** Spontaneous fluctuation of follicular lesions in hidradenitis suppurativa and acne vulgaris
Christos Zouboulis
- A-03-03** Bimekizumab impact on the association between HS symptom severity beyond skin pain and health-related quality of life in BE HEARD EXT
John Ingram
- A-03-05** Network meta-analysis of efficacy and safety of medical interventions for hidradenitis suppurativa
Amit Garg
- A-03-06** And what about Hurley I? Potential factors of disease progression: A nested case-control study of 133 patients
Alejandro Molina-Leyva
- A-03-08** Hidradenitis suppurativa and phenotypes: where do we stand ?
Vincenzo Bettoli
- A-03-10** German Hidradenitis Suppurativa Registry HSBEST: an update of the baseline data
Frenz Ohm
- A-03-14** Establishing expert consensus on core data items for hidradenitis suppurativa clinical care, databases, and real-world research
Raed Alhusayen

Poster Walk 04 – Group 2

- A-03-16** Understanding Therapeutic Burden in Hidradenitis Suppurativa: Insights from a Specialized Clinic
Clara Ureña-Paniego

- A-03-17** TeleVersa (Telemedicine and acne inversa): Exploring the physical and the digital journey of Hidradenitis suppurativa patients in the German Healthcare System
Georgios Kokolakis
- A-03-18** Patients with severe gluteal hidradenitis suppurativa: A descriptive study of 17 cases
Luis Jimenez Briones
- A-03-19** Satisfaction of patients with Hidradenitis suppurativa and their treating dermatologists with the medical care for this skin disease: Data from a German multi-center study
Kerstin Wolk
- A-03-22** Inflammation unchecked: the cancer burden of hidradenitis suppurativa
Noelia Medrano Martínez
- A-03-23** Efficacy and safety of bimekizumab in severe hidradenitis suppurativa: focus on eyelid eczema as an emerging/unreported adverse effect
Giovanna Osorio-Gomez
- A-03-25** Establishment of criteria for hidradenitis suppurativa competence centres using Delphi consensus method
Christos Zouboulis
- Poster Walk 05 – Group 2**
- A-03-26** Adalimumab efficacy in the management of hidradenitis suppurativa data from Lithuania
Tadas Raudonis
- A-03-27** The development and content validation of an instrument to measure drainage in hidradenitis suppurativa: The HiSTORIC Drainage Scale for HS
Bente Villumsen
- A-03-29** Intersecting pathologies: a rare case of hidradenitis suppurativa with cutaneous chronic lupus erythematosus and syphilis
Slavia Gheorghievo
- A-03-31** Existing and novel measures of HS flares and symptom exacerbations indicate high levels of disease control with the Nanobody® sonelokimab in the Phase 2 MIRA trial
John Ingram
- A-03-32** Improvement of HS-related quality of life impairment with the IL-17A- and IL-17F inhibiting Nanobody® sonelokimab: HiSQOL outcomes in the Phase 2 MIRA trial of patients with moderate-to-severe HS
John Ingram

A-04 HS and antimicrobial stewardship**Orals**

- S-02-09** Antimicrobial Stewardship in Hidradenitis Suppurativa: A Multicentre Retrospective Study
Elia Rosi

- S-07-05** Sepsis or systemic inflammatory response syndrome in Hidradenitis Suppurativa? A clinical analysis.
Luciana Gomide

Poster Walk 02 – Group 3

- A-04-01** Real-life data from a tertiary hospital in Northern Greece: A retrospective study on the therapeutic efficacy of Doxycycline on patients suffering from Hidradenitis Suppurativa with Hurley stage I & II and the impact on disease progression
Sofia-Andriani Theodoretou-Charitou

A-05 Social Dermatology in HS**Orals**

- S-03-01** A Survey on Diet in Japanese patients with Hidradenitis Suppurativa compared with Healthy Individuals.
Koremasa Hayama
- S-03-03** Patients' and dermatologists' experience and perspectives on current treatments for people living with hidradenitis suppurativa with draining tunnels
Antonio Martorell
- S-03-04** French translation and validation of the HiSQOL quality of life questionnaire for hidradenitis suppurativa
Sébastien Berros
- S-03-05** Severe acne is a risk factor associated with the severity and phenotype of hidradenitis suppurativa
Qiang Ju
- S-03-09** Hidradenitis suppurativa impacts work life and daily activities more severely than psoriasis
Elena Sotiriou

Poster Walk 03 – Group 1

- A-05-01** A survey on bathing habits in Japanese patients with hidradenitis suppurativa: a comparison with healthy individuals.
Koremasa Hayama
- A-05-03** The impact of hidradenitis suppurativa on sexual health
Marie Gibaux
- A-05-07** Introduction of the psychotherapy group and the hidradenitis suppurativa school in a tertiary care hospital.
Juli Bassas
- A-05-09** Description of the clinical-epidemiological profile of patients with hidradenitis suppurativa in a reference service and assessment of its impact on work activity
afael Rubinho

A-06 Imaging in HS**Orals**

- S-04-01** Tetra Continental Guidelines on the Use of Ultrasound in Hidradenitis Suppurativa: An Expert Delphi Consensus
Ximena Wortsman
- S-04-02** Correlation of quantitative shear wave elastography and the histopathological findings in tunnels of hidradenitis suppurativa: a pilot cross-sectional study
Eva Vilarrasa
- S-04-03** Pilot Project on AI-Assisted Ultrasound for Hidradenitis Suppurativa
Clara Ureña-Paniego
- S-04-04** Role of Ultra-High-Frequency Ultrasound in the Detection and Surgical Management of Microtunnels in Hidradenitis Suppurativa: A Case Series
Giammarco Granieri

Poster Walk 03 – Group 2

- A-06-02** Teledermatology in hidradenitis suppurativa: terms, clinical features, staging and therapeutic decisions agreement,
Carmen García-Moronta
- A-06-04** Perianal fistulizing inflammatory disease: HS or IBD ?
Afsaneh Alavi
- A-06-06** Use of intraoperative ultrasonography in surgical margin determination in hidradenitis suppurativa surgery
Emre Güven

A-07 Surgical treatment**Orals**

- S-09-01** Cost-utility analysis of clinic-based deroofing versus local excision for hidradenitis suppurativa
Sabrina Hundal
- S-09-02** Combined therapy of hidradenitis suppurativa in northern Greece: Do biologic agents and surgical management serve the gold standard?
Sofia-Andriani Theodoretou-Charitou
- S-09-03** Preoperative ultrasound and long-term inflammatory control reduce the risk of recurrence in surgery for hidradenitis suppurativa: an analysis of 206 surgical interventions
Carmen García-Moronta
- S-09-04** Combining deroofing with excision: A holistic approach to hidradenitis surgery
Michael Schenker

- S-09-05** Hybrid wound closure - A new approach to hidradenitis suppurativa surgery
Yusuf Edek
- S-09-07** Modified Incision Gamp; Drainage Procedure (M-I&D): Analysis of Recurrence Rate Compared with the Traditional Method – A Retrospective Analysis of 221 Cases
Antonio Martorell
- S-09-09** Combination of Anti-IL-17 Biologics and Radical Surgery for the Treatment of Patients with HS
Monika Arenbergerova
- Poster Walk 06 – Group 1**
- A-07-03** Two-stage surgical management of anogenital hidradenitis suppurativa in patients on biologic therapy
Lucija Pavljak
- A-07-07** Effectiveness and safety of Secukinumab in combination with surgery in clinical practice
Eva Vilarrasa Rull
- A-07-08** 10 Surgical Instruments for Deroofing in Hidradenitis Suppurativa: versatile and accessible Options.
Pedro Navarro-Guillamon
- A-07-09** Tumescant Drug Delivery (TDD), and a novel tumescent infiltration pump, permit painless, in-office surgery that permanently eliminates hidradenitis suppurativa (HS) pain and drainage.
Jeffrey Klein
- A-07-10** Surgical management in Hidradenitis Suppurativa patients on Bimekizumab therapy: a case series
Alexandra Alturo-Pons
- A-07-11** Punch debridement as an alternative mini-invasive technique on the hidradenitis suppurativa management: One center study
Samed Şahin
- A-07-12** Impact of surgical treatment on pain outcomes in hidradenitis suppurativa patients: a retrospective study
Aslı Tatlıparmak
- A-07-13** Sequential surgical removal of scar tissue in Hurley III hidradenitis suppurativa with tumescent anesthesia in outpatient clinic
Georgios Evangelou
- A-07-14** What to tell your patients about surgical outcomes in hidradenitis suppurativa
Uwe Kirschner
- A-07-16** Effect of Photobiomodulation on Hidradenitis Suppurativa Operative Wound: Case Report
Renata Magalhães

A-08 HS and wound healing**Orals**

- S-09-06** Epigenetic Dysregulation Behind Impaired Wound Healing in Hidradenitis Suppurativa
Uppala Radhakrishna
- Poster Walk 02 – Group 3**
- A-08-01** Moisture-Associated Skin Damage in Hidradenitis Suppurativa: prevalence, risk factors, and management strategies
Valentina Dini
- A-08-03** Plasma Rich in Growth Factors (PRGF) for the Management of Second Intention Closure Healing in Hidradenitis Suppurativa: A Prospective Study in Clinical Practice
Alexandra Alturo-Pons

A-09 Classical HS treatment**Orals**

- S-08-01** Paradoxical psoriasiform reaction to adalimumab in hidradenitis suppurativa
Jose Pascual
- S-08-04** Retrospective evaluation of HS progression using Hurley grade and the scores IHS4 and HS-PGA.
Anne-Sophie Sarkis
- S-08-06** Acitretin in Patients with Follicular Variant of Hidradenitis Suppurativa According to Martorell's Classification: A Retrospective Analysis of a Series of 138 Cases
Antonio Martorell-Calatayud
- S-08-07** Adalimumab in the management of hidradenitis suppurativa: experience of a tertiary center
Patrícia Gomes
- S-08-08** Secukinumab in severe hidradenitis suppurativa (HS): a 2-week interval (Q2) confirms its superiority over 4-week (Q4) in a prospective real life study
Pierre-Andre Becherel
- Poster Walk 06 – Group 2**
- A-09-02** Patient journey, referral patterns and healthcare resource utilization among patients with hidradenitis suppurativa: a nationwide register study
Simon Thomsen
- A-09-03** Hidradenitis suppurativa associated with metabolic syndrome. Novel treatment prospects.
Thomas Fotas
- A-09-04** Treatment patterns in patients with hidradenitis suppurativa in the USA: medication use and surgical procedures from a non-interventional, retrospective cohort study
John Ingram

- A-09-05** Risk factors restricting the appropriateness of oral JAK inhibitor use in patients with hidradenitis suppurativa: a Danish registry-based cohort study
Nikolaj Holgersen
- A-09-06** A Machine Learning Approach to Identify Baseline Predictors of HiSCR From a Phase 2 Study With Povorcitinib
Joslyn Kirby
- A-09-08** Secukinumab faces idradenitis suppurativa and acne: a case report.
Vincenzo Bettoli
- A-09-09** Effectiveness of tetracycline plus rifampicin combination-therapy in hidradenitis suppurativa. A multicenter retrospective observational study
Juli Bassas

A-10 New therapeutic assets**Orals**

- S-05-01** The efficacy of continuous secukinumab treatment over two years, as measured by the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials
Christos Zouboulis
- S-05-02** Early clinical development of CIT-013, a first in class NETosis inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers demonstrating potent inhibition of LPS induced Neutrophil Extracellular Trap formation.
Leonie Middelink
- S-05-03** Depth and Durability of the IHS4 Efficacy Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)
Thrasylvoulos Tzellos
- S-05-04** Depth of the Efficacy Response to Lutikizumab Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)
Hermenio Lima
- S-05-05** A Phase 2 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lutikizumab in Adult Patients with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Falk Bechara
- S-05-06** Metformin in conjunction with doxycycline is not superior to doxycycline monotherapy for Hidradenitis Suppurativa; results of a double-blinded, randomized placebo-controlled trial
Johanna van Huijstee
- S-05-07** Long-term efficacy of LAight therapy in patients with hidradenitis suppurativa
Alexandra Strobel

Poster Walk 04 – Group 3

- A-10-01** The impact of secukinumab on systemic inflammatory markers in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 trials
Brian Kirby
- A-10-03** Hidradenitis suppurativa in a patient with psoriatic arthritis. Therapeutic challenges.
Thomas Fotas
- A-10-05** Efficacy and Safety of Secukinumab in Hidradenitis Suppurativa: Real-Life data from a 24-month retrospective single-site study
Anna Vatalachou
- A-10-08** Improvement in Draining Tunnels in Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)
Falk Bechara
- A-10-09** Real-life data from a tertiary hospital: a retrospective study on the effects of pregnancy, postpartum, and menstrual cycle on hidradenitis suppurativa
Anna Vatalachou
- A-10-11** Effectiveness of topical metformin 30% in the treatment of hidradenitis suppurativa: a new therapeutic approach
Felipe Peirano
- A-10-12** Secukinumab and Hidradenitis suppurativa: Who's responding and why?
Stephanie Heudens
- A-10-14** Real-world data on effectiveness and safety of the jak inhibitor upadacitinib in treating moderate-to-severe hidradenitis suppurativa: a monocentric case series.
Silvia Giordano

Poster Walk 06 – Group 3

- A-10-16** Real-world experience with upadacitinib in refractory Hidradenitis Suppurativa: efficacy and safety in patients with dermatological comorbidities
Alessandra Michelucci
- A-10-17** Psychometric Evaluation of the Hidradenitis Suppurativa Impact Assessment (HSIA) in Adults With Moderate-to-Severe Hidradenitis Suppurativa: Data From a Randomized, Phase 2 Upadacitinib Trial
Alexa Kimball
- A-10-18** Pentoxifylline as an adjunct to the conventional treatment of Elephantiasis nostras-like phenotype of Hidradenitis Suppurativa: a case report
Gavril Poterov
- A-10-19** Psychometric Evaluation of the Hidradenitis Suppurativa Symptom Assessment (HSSA) in Patients With Moderate-to-Severe Hidradenitis Suppurativa: Data From a Randomized, Phase 2 Upadacitinib Trial
Alexa Kimball

- A-10-20** Effectiveness and safety of upadacitinib in hidradenitis suppurativa: a retrospective multicenter study in clinical practice
Eduardo Subiela
- A-10-21** SECU-SPAIN: Real-World Efficacy and Safety of Secukinumab in Hidradenitis Suppurativa - A 1-Year Follow-Up Analysis
Antonio Martorell
- A-10-22** Effectiveness of secukinumab in patients with moderate to severe hidradenitis suppurativa: data from a real-world, managed access program
Maria Constantin
- A-10-23** Bimekizumab impact on HS disease severity measured by IHS4 and draining tunnel count over 2 years: Data from BE HEARD EXT
Christos Zouboulis
- A-10-24** Bimekizumab impact on flare in HS over 2 years: Data from BE HEARD EXT
Haley Naik
- A-10-25** Impact of continuous secukinumab treatment on flare rates over 2 years in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials
Georgios Kokolakis
- A-10-26** Remibrutinib modulates disease-associated autoantibodies in patients with moderate to severe hidradenitis suppurativa: Exploratory biomarker analysis from a randomised, phase 2, double-blind, placebo-controlled platform study
Falk Bechara

Poster Walk 02 – Group 2

- A-10-27** Baseline Characteristics of Patients with Hidradenitis Suppurativa treated with Secukinumab in a Real-World Setting: Interim Results from the ANIMA Study in Germany
Eva Schruf
- A-10-28** Combined blockade of TNFα and OX40L may enhance the immunosuppressive efficacy for the treatment of Hidradenitis Suppurativa
Thomas Leeuw
- A-10-29** Resolution of deep dermal inflammatory lesions (DDILs) with the Nanobody® sonelokimab: Abscess and draining tunnel outcomes from the Phase 2 MIRA trial
Jacek Szepletowski
- A-10-30** IHS4 100 and other IHS4 outcomes with the Nanobody® sonelokimab: Week 24 results from the Phase 2 MIRA trial in patients with moderate-to-severe HS
John Ingram
- A-10-31** The Nanobody® sonelokimab in patients with moderate-to-severe HS: Symptom and quality of life outcomes from the Phase 2 MIRA trial, including pain (NRS 30) and Patient Global Impression of Severity (minimal or absent symptoms)
John Ingram

- A-10-32** Evidence of a role for IL-17F in the inflammatory mechanisms underlying hidradenitis suppurativa (HS), including in deep dermal tunnels
Kristian Reich
- A-10-33** Patient Perspectives on topicals in Hidradenitis Suppurativa: Insights from a Danish Online Survey Cohort
Gregor B.E. Jemec
- A-10-34** Effect of Photobiomodulation on Lesions of People with Hidradenitis SUPURATIVA
Renata Magalhães

A-11 HS and AI**Orals**

- S-07-03** Analysis of mortality in patients with chronic immunologic skin diseases from the Spanish big data-based DERMACLEAR study: focus on hidradenitis suppurativa.
Laoise Griffin

A-12 HS and mental health**Orals**

- S-03-08** The psycho-emotional impact of Hidradenitis Suppurativa/Acne Inversa: patient's bodily experience, psychiatric comorbidity, self-esteem, coping styles and resilience. A cross-sectional study.
Lucrezia Pacetti
- Poster Walk 02 – Group 3**
- A-12-03** Quality of life in Hidradenitis Suppurativa patients: a bridge between disease indices and patient-reported outcomes
Flavia Manzo Margiotta
- A-12-04** A 66-Year-Old Transgender Woman with Hidradenitis Suppurativa: Challenges in Management and Considerations for Providers
Tatjana Steybe
- A-12-05** Impact of Hidradenitis Suppurativa on Patients' Sexuality: A Holistic Approach Using a Self-Administered Questionnaire
Léonie Krasilowycz

INDUSTRY PROGRAM AND EXHIBITION



This is a representative patient image.

TOGETHER, WE CAN CHANGE THAT

Often underrecognized and undiagnosed, the chronic and progressive inflammation of HS may wreak havoc on patients' lives by causing debilitating pain, irreversible scarring, and emotional burden.¹⁻⁶ Don't wait for HS to progress.



Visit our Novartis booth to learn more

 NOVARTIS

HS=hidradenitis suppurativa.

References: 1. Daxhelet M et al. *Dermatology*. 2020;236(5):431-438. 2. Kokolakis G et al. *Dermatology*. 2020;236(5):421-430. 3. Kirby JS. *J Am Acad Dermatol*. 2016;74(6):1269-1270. 4. Matusiak L et al. *Acta Derm Venereol*. 2010;90(3):264-268. 5. Garg A et al. *J Am Acad Dermatol*. 2020;82(2):366-376. 6. van der Zee HH et al. *Br J Dermatol*. 2022;186(2):355-356.

INDUSTRY SYMPOSIA

Thursday, February 13, 2025

13:00–14:00 **Industry Lunch Symposium – Novartis** **Early Intervention and Disease Modification in HS: Can We** **Change the Course of the Disease** Room Alpha

Welcome and Introductions
Prof. John Ingram

The pathophysiology and disease variability of HS: a window for early intervention
Dr. Kelsey van Straalen

Clinical evidence supporting early intervention
Dr. Antonio Martorell

Guideline implementation, and practical approaches to early diagnosis and intervention
Prof. John Ingram

Panel discussion

14:15–15:15 **Industry Lunch Symposium – UCB** **Unveiling the Role of Dual Inhibition of IL-17A and IL-17F in HS** Room Alpha

Welcome and Introductions
Assoc. Prof. Rūta Gancevičienė

How do IL-17A and IL-17F impact HS?
Prof. John Ingram

What are the latest bimekizumab clinical data?
Prof. Jacek Szepietowski

How does bimekizumab's efficacy translate to clinical practice?
Dr. Sylke Schneider-Burrus

Panel discussion

Friday, February 14, 2025

12:45–13:45 **Industry Lunch Symposium – AbbVie** **New Frontiers in Hidradenitis Suppurativa** Room Alpha

Welcome and Introductions
Dr. Tadas Raudonis

What is front of mind for our patients' needs?
Assoc. Prof. Marni Wiseman

New frontiers in HS pathogenesis
Dr. Laura Savage

How can we be pioneers in HS patient care?
Assoc. Prof. Marni Wiseman, Dr. Laura Savage


Panel discussion





**For your HS
patients, a seat
can feel like
a thousand
piercing needles.**

Visit our UCB stand to discover the Unbearable Home, a small house that highlights the big impact of living with HS.



SPONSORS

We would like to thank all our sponsors for their support and collaboration!

Platinum Sponsors

ABBVIE

www.abbvie.com

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, such as Hidradenitis Suppurativa.



NOVARTIS

www.novartis.com

At Novartis we are reimaging medicine. As a leading global medicines company, we use innovative science and digital technologies to deliver high-value medicines for challenging and often-ignored conditions. We are continuing to bring unimagined possibilities to life through our relentless determination. With human compassion, commitment, and unwavering scientific curiosity, we develop and drive access to medicines for those who need them most.



UCB

www.ucb.com/disease-areas/hidradenitis-suppurativa

UCB is a global biopharmaceutical company dedicated to discovering and developing innovative medicines that transform patients' lives. We are committed to putting patients at the centre of our world, with a focus in immunology including hidradenitis suppurativa.

UCB is working to advance science and embrace new knowledge. We leverage scientific advances in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs and practical solutions.



Inspired by patients.
Driven by science.

Silver Sponsors

INCYTE

www.incyte.com



MOONLAKE IMMUNOTHERAPEUTICS

www.moonlaketx.com



New Frontiers in Hidradenitis Suppurativa

Friday, 14 February 2025
12:45–13:45 EET

IN THIS SESSION, WE WILL:

- Explore current insights on unmet needs in HS
- Delve into deeper understanding of emerging therapeutic targets
- Discuss strategies and opportunities to elevate expectations in HS management

Chair:



Dr Tadas Raudonis
Vilnius University,
Vilnius, Lithuania



Dr Marni Wiseman
University of Manitoba,
Winnipeg, Manitoba, Canada




Dr Laura Savage
Leeds Teaching Hospitals NHS Trust,
Leeds, England, United Kingdom



This symposium is open to health care specialists only.
This symposium is organized and funded by AbbVie.
ABBV-AA-03827-E | V1 | Approved December 2024

INDUSTRY BOOTH PLAN

Conference & Event Center, 1st floor
Radisson Blu Hotel Lietuva



LIST OF BOOTHS:

1. Novartis
2. AbbVie
3. MoonLake Immunotherapeutics
4. UCB
5. Incyte
6. UCB

OPENING HOURS:

Wednesday, February 12, 2025
08:00–20:00

Thursday, February 13, 2025
08:00–18:30

Friday, February 14, 2025
08:00–17:30



IMPRINT

Scientific Organizer

European Hidradenitis Suppurativa
Foundation e.V.
Auenweg 38, 06847 Dessau-Rosslau
www.ehsf.eu

Prof. Dr. Christos C. Zouboulis
President of the EHSF e.V.

Legal Organizer & PCO

MCI Deutschland GmbH
Markgrafenstrasse 56
10117 Berlin
T: +49 30 20459230
F: +49 30 2045950

Congress venue

Radisson Blu Hotel Lietuva,
Konstitucijos pr. 20, Vilnius
09308 Vilniaus m. sav.
Lithuania

Contact

Project Management
Anahit Balayan
T: +49 30 204 59 337
ehsf@wearemci.com

Sponsoring/Exhibition
Alina Iakupova
T: +49 30 204 59 334
ehsf-sponsoring@wearemci.com

Printing date: 27.01.2025

